Progressive supranuclear-palsy (PSP) is a very rare brain disease and until recently, it was almost unheard of. Along with many neurodegenerative diseases, it has a high unmet medical need.
A licensing agreement has been signed that will give Spanish pharma company, Ferrer, worldwide rights to a treatment for progressive supranuclear palsy (PSP).